Copyright © 2003 by the European Society of Cardiology.
The EuroHeart Failure Survey programmea survey on the quality of care among patients with heart failure in Europe
Part 2: treatment
The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology*,a Paris, France;b Zürich, Switzerland;c Göteborg, Sweden;d Kingston upon Hull, UK;e Valencia, Spain;f Clichy, France;g Berlin, Germany;h Bergamo, Italy;i Groningen, The Netherlands;j Birmingham, UK;k Warsaw, Poland;l Lisbon, Portugal;m Moscow, Russia;n Budapest, Hungary;o Prague, Czech Republic;p Department of Primary Care & General Practice, University of Birmingham, UK;q Practice, Newcastle, UK
Received September 6, 2002; accepted September 18, 2002 * Corresponding author. Michel Komajda, Institut de Cardiologie, GH Pitié-Salpêtrière, 47-83 Bld de l'Hôpital, 75013 Paris, France.
E-mail address: j.g.cleland{at}hull.ac.uk
Background National surveys suggest that treatment of heart failure in daily practice differs from guidelines and is characterized by underuse of recommended medications. Accordingly, the Euro Heart Failure Survey was conducted to ascertain how patients hospitalized for heart failure are managed in Europe and if national variations occur in the treatment of this condition.
Methods The survey screened discharge summaries of 11 304 patients over a 6-week period in 115 hospitals from 24 countries belonging to the ESC to study their medical treatment.
Results Diuretics (mainly loop diuretics) were prescribed in 86.9% followed by ACE inhibitors (61.8%), beta-blockers (36.9%), cardiac glycosides (35.7%), nitrates (32.1%), calcium channel blockers (21.2%) and spironolactone (20.5%). 44.6% of the population used four or more different drugs. Only 17.2% were under the combination of diuretic, ACE inhibitors and beta-blockers. Important local variations were found in the rate of prescription of ACE inhibitors and particularly beta-blockers. Daily dosage of ACE inhibitors and particularly of beta-blockers was on average below the recommended target dose. Modelling-analysis of the prescription of treatments indicated that the aetiology of heart failure, age, co-morbid factors and type of hospital ward influenced the rate of prescription. Age <70 years, male gender and ischaemic aetiology were associated with an increased odds ratio for receiving an ACE inhibitor. Prescription of ACE inhibitors was also greater in diabetic patients and in patients with low ejection fraction (<40%) and lower in patients with renal dysfunction. The odds ratio for receiving a beta-blocker was reduced in patients >70 years, in patients with respiratory disease and increased in cardiology wards, in ischaemic heart failure and in male subjects. Prescription of cardiac glycosides was significantly increased in patients with supraventricular tachycardia/atrial fibrillation. Finally, the rate of prescription of antithrombotic agents was increased in the presence of supraventricular arrhythmia, ischaemic heart disease, male subjects but was decreased in patients over 70.
Conclusion Our results suggest that the prescription of recommended medications including ACE inhibitors and beta-blockers remains limited and that the daily dosage remains low, particularly for beta-blockers. The survey also identifies several important factors including age, gender, type of hospital ward, co morbid factors which influence the prescription of heart failure medication at discharge.
Key Words: Heart failure Medical treatment Survey
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M J Lenzen, A Rosengren, W J M S. op Reimer, F Follath, E Boersma, M L Simoons, J G F Cleland, and M Komajda Management of patients with heart failure in clinical practice: differences between men and women Heart, March 1, 2008; 94(3): e10 - e10. [Abstract] [Full Text] [PDF] |
||||
![]() |
E D Nicol, B Fittall, M Roughton, J G F Cleland, H Dargie, and M R Cowie NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland Heart, February 1, 2008; 94(2): 172 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Khunti, M. Stone, S. Paul, J. Baines, L. Gisborne, A. Farooqi, X. Luan, and I. Squire Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial Heart, November 1, 2007; 93(11): 1398 - 1405. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ekman and K. Swedberg Patients' Persistence of Evidence-Based Treatment of Chronic Heart Failure: A Treatment Paradox Circulation, August 14, 2007; 116(7): 693 - 695. [Full Text] [PDF] |
||||
![]() |
G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom, T. K. Schramm, M. L. Hansen, P. Buch, R. Sorensen, F. Folke, N. Gadsboll, S. Rasmussen, et al. Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes Circulation, August 14, 2007; 116(7): 737 - 744. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, E. Donal, J. F. Aupetit, M. C. Aumont, M. Galinier, J. C. Eicher, et al. Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure: The STARS-BNP Multicenter Study J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1733 - 1739. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Siirila-Waris, J. Lassus, J. Melin, K. Peuhkurinen, M. S. Nieminen, V.-P. Harjola, and for the FINN-AKVA study group Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure Eur. Heart J., December 2, 2006; 27(24): 3011 - 3017. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Christ, K. Laule-Kilian, W. Hochholzer, T. Klima, T. Breidthardt, A. P. Perruchoud, and C. Mueller Gender-Specific Risk Stratification With B-Type Natriuretic Peptide Levels in Patients With Acute Dyspnea: Insights From the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation Study J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1808 - 1812. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Nieminen, D. Brutsaert, K. Dickstein, H. Drexler, F. Follath, V.-P. Harjola, M. Hochadel, M. Komajda, J. Lassus, J. L. Lopez-Sendon, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population Eur. Heart J., November 2, 2006; 27(22): 2725 - 2736. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Eurlings, J. L. Januzzi, and Y. M. Pinto Is acute heart failure a highly prevalent orphan disease? Eur. Heart J., November 2, 2006; 27(22): 2619 - 2620. [Full Text] [PDF] |
||||
![]() |
J.-C. Tardif and C. Berry From coronary artery disease to heart failure: potential benefits of ivabradine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D24 - D29. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nair, B. Sealove, J. L. Halperin, G. Webber, and V. Fuster Anticoagulation in patients with heart failure: who, when, and why? Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E32 - E38. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Jezior and L. E. Sullenberger Letter Regarding Article by Newby et al, "Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease" Circulation, August 8, 2006; 114(6): e240 - e240. [Full Text] [PDF] |
||||
![]() |
R. Willenheimer and P. Lechat New concepts in managing patients with chronic heart failure: the evolving importance of beta-blockade Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C3 - C4. [Full Text] [PDF] |
||||
![]() |
P. Lechat The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C5 - C12. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Silke Beta-blockade in CHF: pathophysiological considerations Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C13 - C18. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Follath Beta-blockade today: the gap between evidence and practice Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C28 - C34. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ponikowski Rationale and design of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C35 - C42. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Willenheimer How to begin treatment in chronic heart failure? Results of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C43 - C50. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lechat and R. Willenheimer Discussion summary: key clinical questions Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C58 - C60. [Full Text] [PDF] |
||||
![]() |
L. G. Olsson, K. Swedberg, A. Ducharme, C. B. Granger, E. L. Michelson, J. J.V. McMurray, M. Puu, S. Yusuf, M. A. Pfeffer, and on behalf of the CHARM Investigators Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1997 - 2004. [Abstract] [Full Text] [PDF] |
||||
![]() |
P A Mehta and M R Cowie Gender and heart failure: a population perspective Heart, May 1, 2006; 92(suppl_3): iii14 - iii18. [Full Text] [PDF] |
||||
![]() |
M. Stramba-Badiale, K. M. Fox, S. G. Priori, P. Collins, C. Daly, I. Graham, B. Jonsson, K. Schenck-Gustafsson, and M. Tendera Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology Eur. Heart J., April 2, 2006; 27(8): 994 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. B.-L. Rocca, J. Capraro, and W. Kiowski Compliance by Referring Physicians With Recommendations on Heart Failure Therapy from a Tertiary Center Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 85 - 92. [Abstract] [PDF] |
||||
![]() |
R J Shelton, A S Rigby, J G F Cleland, and A L Clark Effect of a community heart failure clinic on uptake of {beta} blockers by patients with obstructive airways disease and heart failure Heart, March 1, 2006; 92(3): 331 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Brophy Rehabilitating digoxin Eur. Heart J., January 2, 2006; 27(2): 127 - 129. [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade, F. Zannad, G. Sopko, L. Klein, I. L. Pina, M. A. Konstam, B. M. Massie, E. Roland, S. Targum, S. P. Collins, et al. Acute Heart Failure Syndromes: Current State and Framework for Future Research Circulation, December 20, 2005; 112(25): 3958 - 3968. [Full Text] [PDF] |
||||
![]() |
M. J. Lenzen, E. Boersma, W. J.M. Scholte op Reimer, A. H.M.M. Balk, M. Komajda, K. Swedberg, F. Follath, M. Jimenez-Navarro, M. L. Simoons, and J. G.F. Cleland Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure Eur. Heart J., December 2, 2005; 26(24): 2706 - 2713. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Squire Managing patients with heart failure: the reality of clinical practice Eur. Heart J., December 2, 2005; 26(24): 2611 - 2613. [Full Text] [PDF] |
||||
![]() |
J. J.V. McMurray The role of angiotensin II receptor blockers in the management of heart failure Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J10 - J14. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Maggioni Review of the new ESC guidelines for the pharmacological management of chronic heart failure Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J15 - J20. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Swedberg and I. Ekman Integrating heart failure guidelines into clinical practice Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J21 - J25. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy, and A. Laupacis Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure JAMA, September 14, 2005; 294(10): 1240 - 1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
A M Clark, I N Findlay, and for the Have a Heart Paisley IT Group Improving evidence based cardiac care and policy implementation over the patient journey: the potential of coronary heart disease registers Heart, September 1, 2005; 91(9): 1127 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Komajda, P. Lapuerta, N. Hermans, J. R. Gonzalez-Juanatey, D. J. van Veldhuisen, E. Erdmann, L. Tavazzi, P. Poole-Wilson, and C. Le Pen Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey Eur. Heart J., August 2, 2005; 26(16): 1653 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
A L Clark and J G F Cleland Multidisciplinary interventions in heart failure Heart, July 1, 2005; 91(7): 849 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Bassand, S. Priori, and M. Tendera Evidence-based vs. 'impressionist' medicine: how best to implement guidelines Eur. Heart J., June 2, 2005; 26(12): 1155 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Daly, F. Clemens, J. L. L. Sendon, L. Tavazzi, E. Boersma, N. Danchin, F. Delahaye, A. Gitt, D. Julian, D. Mulcahy, et al. The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina Eur. Heart J., May 2, 2005; 26(10): 996 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
T A McDonagh Lessons from the management of chronic heart failure Heart, May 1, 2005; 91(suppl_2): ii24 - ii27. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade and F. Zannad Modern management of acute heart failure syndromes Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B3 - B7. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade and G. Filippatos Reassessing treatment of acute heart failure syndromes: the ADHERE Registry Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B13 - B19. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. McMurray Making sense of SENIORS Eur. Heart J., February 1, 2005; 26(3): 203 - 206. [Full Text] [PDF] |
||||
![]() |
P. Roman-Sanchez, P. Conthe, J. Garcia-Alegria, J. Forteza-Rey, M. Montero, C. Montoto, and for the Heart Failure Working Group of the Spanish Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey QJM, February 1, 2005; 98(2): 127 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J.V. McMurray and M. A. Pfeffer The year in heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405. [Full Text] [PDF] |
||||
![]() |
J. B. Young, M. E. Dunlap, M. A. Pfeffer, J. L. Probstfield, A. Cohen-Solal, R. Dietz, C. B. Granger, J. Hradec, J. Kuch, R. S. McKelvie, et al. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low-Left Ventricular Ejection Fraction Trials Circulation, October 26, 2004; 110(17): 2618 - 2626. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Rumsfeld and F. A. Masoudi Heart failure disease management works, but will it succeed? Eur. Heart J., September 2, 2004; 25(18): 1565 - 1567. [Full Text] [PDF] |
||||
![]() |
J. Gonseth, P. Guallar-Castillon, J. R. Banegas, and F. Rodriguez-Artalejo The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports Eur. Heart J., September 2, 2004; 25(18): 1570 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Gustafsson and J. M. O. Arnold Heart failure clinics and outpatient management: review of the evidence and call for quality assurance Eur. Heart J., September 2, 2004; 25(18): 1596 - 1604. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C Deedwania, S. Gottlieb, J. K Ghali, F. Waagstein, J. C. Wikstrand, and for the MERIT-HF Study Group Efficacy, safety and tolerability of {beta}-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure Eur. Heart J., August 1, 2004; 25(15): 1300 - 1309. [Abstract] [Full Text] [PDF] |
||||
![]() |
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362. [Full Text] [PDF] |
||||
![]() |
A. Bundkirchen and R. H.G Schwinger Epidemiology and economic burden of chronic heart failure Eur. Heart J. Suppl., August 1, 2004; 6(suppl_D): D57 - D60. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.J Lenzen, W.J.M Scholte op Reimer, E Boersma, P.J.M.J Vantrimpont, F Follath, K Swedberg, J Cleland, and M Komajda Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey Eur. Heart J., July 2, 2004; 25(14): 1214 - 1220. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Majumdar, F. A. McAlister, and C. D. Furberg From knowledge to practice in chronic cardiovascular disease: a long and winding road J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1738 - 1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Bauman and R. L. Talbert Pharmacodynamics of{beta}-Blockers in Heart Failure: Lessons from the Carvedilol Or Metoprolol European Trial Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 117 - 128. [Abstract] [PDF] |
||||
![]() |
J. G. F. Cleland and A. L. Clark Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: Too many cooks will spoil the broth J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1234 - 1237. [Full Text] [PDF] |
||||







